삼성서울병원

Ko En

Hematology-Oncology Kim, Won Seog M.D

Expertise
malignant lymphoma, CAR T-Cell therapy
Treament Schedule 04 月
DATE
MON
01
TUE
02
WEB
03
THU
04
FRI
05
SAT
06
SUN
07
MON
08
TUE
09
WEB
10
THU
11
FRI
12
SAT
13
SUN
14
MON
15
TUE
16
WEB
17
THU
18
FRI
19
SAT
20
SUN
21
MON
22
TUE
23
WEB
24
THU
25
FRI
26
SAT
27
SUN
28
MON
29
TUE
30
AM
PM
Treament Schedule 05 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical Education

Ph.D. in Medicine College of Medicine, Seoul National University
Master of Science College of Medicine, Seoul National University

Post-Graduate Training

Fellowship   1996~1997 Fellowship Section of Medical Oncology, Dept. of Internal Medicine, Samsung Medical Center. Seoul, Korea
1995~1996 Fellowship Section of Medical Oncology, Dept. of Internal Medicine, Seoul National University Hospital
Residency   1991~1995 Residency Dept. of Internal Medicine, Seoul National University Hospital
Internship   1990~1991 Internship Seoul National University Hospital

Professional Appointments

2010~present Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
2004~2010 Associate Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
2000~2004 Assistant Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
1998~2000 Full-time lecturer Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea
1997~1998 Staff Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center, Seoul, Korea

Professional Memberships

Member Korean Medical Association
Member Korean Association of Internal Medicine
Member Korean Society of Hematology
Chairman lymphoma working party of Korean society of hematology
Chairman Consortium of improving survival of lymphoma ( CISL)
Founding member Asian lymphoma study group ( ALSG)
Co-Chair T cell lymphoma forum (TCLF)

Selected Publications

  • LANCET HAEMATOL 2021 Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial Straus1, DJ; Dlugosz-Danecka, M; Connors, JM; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; Walewski, J; Ramchandren, R; Zinzani, PL; Hutchings, M; Munoz, J; Lee, HJ; Kim, WS; Advani, R; Ansell, SM; Younes, A; Gallamini, A; Liu, R; Little, M; Fenton, K; Fanale, M; Radford, J
    View PubMed
  • BLOOD ADV 2021 10.1182/bloodadvances.2020004074 Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma Tam1, CS; Opat, S; Simpson, D; Cull, G; Munoz, J; Phillips, TJ; Kim, WS; Rule, S; Atwal, SK; Wei, R; Novotny, W; Huang, J; Wang, M; Trotman, J
    View PubMed
  • ANTIVIR RES 2021 10.1016/j.antiviral.2021.105063 Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications Kim1, JH; Kim, WS; Park, C
    View PubMed
  • SCI REP-UK 2021 10.1038/s41598-021-89754-8 EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma Lee1, JY; Kim, JH; Bang, H; Cho, J; Ko, YH; Kim, SJ; Kim, WS
    View PubMed
  • EXP HEMATOL ONCOL 2021 10.1186/s40164-021-00224-3 Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas Yoon1, SE; Cho, J; Kim, YJ; Ko, YH; Park, WY; Kim, SJ; Kim, WS
    View PubMed